Literature DB >> 21288697

Mental state attribution in schizophrenia: what distinguishes patients with "poor" from patients with "fair" mentalising skills?

M Brüne1, D Schaub.   

Abstract

PURPOSE: Although many patients with schizophrenia are impaired in mental states attribution abilities, a significant number perform within normal or near-normal ranges in mental state attribution tasks. No studies have analysed cognitive or behavioural differences between patients with - to some extent - preserved mental state attribution skills and those with poor mentalising abilities.
MATERIAL AND METHODS: To examine characteristics of "poor" and "fair" mentalisers, 58 patients with schizophrenia performed a mental state attribution task, a test of general intelligence, and two executive functioning tests. "Poor" and "fair" mentalising skills were defined according to a median-split procedure; the median score in the patient group was also within two standard deviations of the control group. In addition, patients' social behavioural skills and psychopathological profiles were rated.
RESULTS: Patients performing within normal or near normal ranges on the mental state attribution task had fewer social behavioural abnormalities than patients with poor mentalising abilities (even when controlled for intelligence), but did not differ in executive functioning. Fair mental state performers showed less disorganisation and excitement symptoms than poor performers. The degree of disorganisation mediated the influence of mental state attribution on social behavioural skills.
CONCLUSIONS: Schizophrenia patients with (partially) preserved mentalising skills have fewer behavioural problems in the social domain than patients with poor mentalising abilities. Conceptual disorganisation mediates the prediction of social behavioural skills through mentalising skills, suggesting that disorganised patients may require special attention regarding social-cognitive skills training.
Copyright © 2010 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21288697     DOI: 10.1016/j.eurpsy.2010.10.002

Source DB:  PubMed          Journal:  Eur Psychiatry        ISSN: 0924-9338            Impact factor:   5.361


  7 in total

Review 1.  [Social psychiatry and neurobiology : A long overdue convergence exemplified by schizophrenia].

Authors:  W Kawohl; C Wyss; P Roser; M Brüne; W Rössler; G Juckel
Journal:  Nervenarzt       Date:  2017-05       Impact factor: 1.214

2.  Persons With Schizophrenia Misread Hemingway: A New Approach to Study Theory of Mind in Schizophrenia.

Authors:  Judit Fekete; Zsuzsanna Pótó; Eszter Varga; Tímea Csulak; Orsolya Zsélyi; Tamás Tényi; Róbert Herold
Journal:  Front Psychiatry       Date:  2020-05-07       Impact factor: 4.157

Review 3.  Can antipsychotics improve social cognition in patients with schizophrenia?

Authors:  Katarzyna Kucharska-Pietura; Ann Mortimer
Journal:  CNS Drugs       Date:  2013-05       Impact factor: 5.749

4.  Social cognitive and neurocognitive deficits in inpatients with unilateral thalamic lesions - pilot study.

Authors:  Ewelina Wilkos; Timothy Jb Brown; Ksenia Slawinska; Katarzyna A Kucharska
Journal:  Neuropsychiatr Dis Treat       Date:  2015-04-10       Impact factor: 2.570

5.  Using fiction to assess mental state understanding: a new task for assessing theory of mind in adults.

Authors:  David Dodell-Feder; Sarah Hope Lincoln; Joseph P Coulson; Christine I Hooker
Journal:  PLoS One       Date:  2013-11-07       Impact factor: 3.240

6.  Do patients with schizophrenia use prosody to encode contrastive discourse status?

Authors:  Amandine Michelas; Catherine Faget; Cristel Portes; Anne-Sophie Lienhart; Laurent Boyer; Christophe Lançon; Maud Champagne-Lavau
Journal:  Front Psychol       Date:  2014-07-18

7.  Recognition of Social Rule Violation in "Deficit Syndrome" Schizophrenia: A Study Using Economic Games.

Authors:  Christian Claassen; Robyn Langdon; Martin Brüne
Journal:  Front Psychiatry       Date:  2020-08-21       Impact factor: 4.157

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.